Cerus/CERS

$2.23

0.9%
-
1D1W1MYTD1YMAX

About Cerus

Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as platelets, plasma, red blood cells. Its product or product candidate under development include INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, red blood cell and IFC transfusion products.

Ticker

CERS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

William Greenman

Employees

309

Headquarters

Concord, United States

Cerus Metrics

BasicAdvanced
$400.45M
Market cap
-
P/E ratio
-$0.28
EPS
1.31
Beta
-
Dividend rate

What the Analysts think about Cerus

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
85.2% upside
High $6.00
Low $2.50
$2.23
Current price
$4.13
Average price target

Cerus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-15.25% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$47.2M
-1.05%
Net income
$-7.2M
-45.45%
Profit margin
-15.25%
-44.89%

Cerus Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 42.86%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.08
-$0.09
-$0.06
-$0.03
-
Expected
-$0.05
-$0.08
-$0.06
-$0.05
-$0.02
Surprise
68.42%
20%
7.14%
-42.86%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Cerus stock

Buy or sell Cerus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing